AR118619A1 - Anticuerpos de unión a pd-1 - Google Patents

Anticuerpos de unión a pd-1

Info

Publication number
AR118619A1
AR118619A1 ARP200100982A ARP200100982A AR118619A1 AR 118619 A1 AR118619 A1 AR 118619A1 AR P200100982 A ARP200100982 A AR P200100982A AR P200100982 A ARP200100982 A AR P200100982A AR 118619 A1 AR118619 A1 AR 118619A1
Authority
AR
Argentina
Prior art keywords
antibodies
binding
neutralize
antigen
seq
Prior art date
Application number
ARP200100982A
Other languages
English (en)
Inventor
Shengfeng Li
Shizhong Liang
Shujun Pei
Jian Lin
Haitao Yue
Original Assignee
Bio Thera Solutions Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Thera Solutions Ltd filed Critical Bio Thera Solutions Ltd
Publication of AR118619A1 publication Critical patent/AR118619A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Abstract

En el presente documento, se describen anticuerpos que se unen a PD-1 y que comprenden una o más CDR seleccionadas de secuencias de aminoácidos de SEQ ID Nº 13, 14, 15, 16, 17 y 18. Los anticuerpos tienen afinidad alta y tasa de disociación baja para PD-1, así como la capacidad para neutralizar PD-1 in vitro. Los anticuerpos descritos en este documento pueden ser anticuerpos de longitud completa o fragmentos unidos a antígenos. Los anticuerpos pueden utilizarse para detectar PD-1 y elementos similares.
ARP200100982A 2019-04-10 2020-04-08 Anticuerpos de unión a pd-1 AR118619A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910286677 2019-04-10

Publications (1)

Publication Number Publication Date
AR118619A1 true AR118619A1 (es) 2021-10-20

Family

ID=72750942

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100982A AR118619A1 (es) 2019-04-10 2020-04-08 Anticuerpos de unión a pd-1

Country Status (7)

Country Link
US (1) US20220204623A1 (es)
EP (1) EP3931223A4 (es)
JP (1) JP2022538375A (es)
CN (2) CN117603355A (es)
AR (1) AR118619A1 (es)
TW (1) TW202104262A (es)
WO (1) WO2020207432A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115776898A (zh) * 2020-07-07 2023-03-10 百奥泰生物制药股份有限公司 双特异性抗体及其应用
EP4226942A1 (en) * 2020-10-11 2023-08-16 Bio-Thera Solutions, Ltd. Use of anti-pd-1 antibody in combination medication
CN115466328A (zh) * 2021-06-11 2022-12-13 广东菲鹏制药股份有限公司 抗pd-1人源化抗体或其抗原结合片段及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104945508B (zh) * 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
RU2750675C1 (ru) * 2015-10-02 2021-07-01 Симфоген А/С Антитела против pd-1 и композиции
AU2018242880A1 (en) * 2017-03-27 2019-10-31 Fuso Pharmaceutical Industries, Ltd. Anti-PD-L1 antibody for detecting PD-L1
WO2018217227A1 (en) * 2017-05-24 2018-11-29 Immunomedics, Inc. Novel anti-pd-1 checkpoint inhibitor antibodies that block binding of pd-l1 to pd-1
CN108997499B (zh) * 2018-09-12 2020-07-31 首都医科大学附属北京胸科医院 一种抗人pd-l1抗体及其应用

Also Published As

Publication number Publication date
US20220204623A1 (en) 2022-06-30
CN111808190A (zh) 2020-10-23
WO2020207432A1 (en) 2020-10-15
JP2022538375A (ja) 2022-09-02
TW202104262A (zh) 2021-02-01
CN117603355A (zh) 2024-02-27
EP3931223A1 (en) 2022-01-05
EP3931223A4 (en) 2023-07-12
CN111808190B (zh) 2023-12-12

Similar Documents

Publication Publication Date Title
AR118619A1 (es) Anticuerpos de unión a pd-1
CY1122020T1 (el) Μορια δεσμευσης σε cd3 ικανα να δεσμευονται σε ανθρωπινα και μη ανθρωπινα cd3
CO2018006299A2 (es) Compuestos novedosos
AR110979A1 (es) Moléculas de unión a cd70 y métodos de uso de las mismas
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
MY191649A (en) Antibodies to tigit
EA201790087A1 (ru) Ковалентно связанные диатела, обладающие иммунореактивностью с pd-1 и lag-3, и способы их применения
AR075504A1 (es) Moleculas de anticuerpos que tienen especificidad para el ox40 humano
PE20220505A1 (es) Moleculas de union a tigit y pd-1/tigit
AR101400A1 (es) Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
NZ721184A (en) Therapeutic peptides
MX2014005546A (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
EA201792307A1 (ru) Способы репарации и регенерации тканей
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
BR112018015754A2 (pt) anticorpos anti-tnf, composições, métodos e uso para o tratamento ou prevenção de diabetes tipo 1
PH12014501410A1 (en) Compositions and methods for antibodies targeting factor p
MX2020010732A (es) Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl.
MX360155B (es) Anticuerpos que se unen al ligando 1a tipo tnf y sus usos.
MX2015005719A (es) Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas.
AR106307A1 (es) Anticuerpos de hidratos de carbono, composiciones farmacéuticas y usos de los mismos
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
CY1124456T1 (el) Antισωματα αντι-5τ4 και συζευγματα φαρμακου αντισωματων